FTC Asks AbbVie, Others For Deal Docs In Pay-For-Delay Suit
Law360, New York (July 27, 2015, 2:47 PM EDT) -- The Federal Trade Commission and private plaintiffs suing AbbVie Products LLC and other drugmakers over patent pay-for-delay settlements for testosterone drug AndroGel moved Friday to force the companies to turn over details of their settlement negotiations.
The plaintiffs said AbbVie and fellow defendants Actavis Inc., Par Pharmaceutical Cos. Inc. and Paddock Laboratories Inc. have withheld various documents as privileged but contend the information is not covered by attorney-client privilege. The FTC and others asked the court to force the drugmakers to produce the documents and allow witnesses to be questioned about settlement discussions conducted by the companies’ lawyers in 2006.
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!